 - Premenopausal and postmenopausal female breast cancer patient with histological proven ER andor PR positive, HER2 negative breast cancer based on the most recent assessment of ER and PR status from primary breast cancer or from recurrent or metastatic disease. If a patient is premenopausal by clinical and analytical assessment defined as having premenopausal follicle stimulating hormone FSH andor plasma estradiol levels, she should also receive a LHRH agonist. 